EGEN

Company Logo: 

EGEN, Inc. is a privately held biopharmaceutical company specializing in nucleic acid (DNA, RNAi) therapeutics and delivery via proprietary TheraPlas™ and TheraSilence™ technologies. EGEN’s lead product, EGEN-001, was listed in Top 100 Investigational Drugs by R&D Directions and selected to Windhover’s Top 10 Oncology Drugs Available for Partnering. The company will begin two EGEN-001 phase II ovarian cancer trials in mid 2010 in conjunction with the Gynecological Oncology Group/National Cancer Institute.